Literature DB >> 1960384

Hepatotoxicity of antidepressants.

M Davis1.   

Abstract

Detection of abnormal liver function tests in a patient receiving an antidepressant or other psychopharmacological agent presents a major problem to the clinician, who must decide whether or not to withdraw a drug which may be of central importance in the patient's management. Experimental studies have clearly demonstrated a hepatotoxic potential for many of these compounds, but in the clinical situation the picture is far less clear cut because there are remarkably little published data on the incidence of liver damage from these agents in man. Furthermore, interpretation of abnormal liver function tests and ascribing them to a drug rather than to an alternative cause is not always straightforward. Hepatic drug reactions fall into two categories; those which are predictable and dose-related (e.g. acute hepatic necrosis following suicidal overdose with the analgesic paracetamol), and those which are unpredictable and dose-independent, complicating treatment with a drug at therapeutic dosage (Davis and Williams, 1985). Most hepatic drug reactions, including those caused by antidepressants, fall into the second category. The spectrum of severity may vary widely, from minor abnormalities in biochemical liver function tests with no constitutional disturbance, to severe hepatitis and/or cholestasis which can sometimes be fatal. Chronic liver disease has also been described.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1960384     DOI: 10.1097/00004850-199100620-00004

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  2 in total

1.  Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: a case report.

Authors:  Deniz Gökengin; Tansu Yamazhan
Journal:  Ann Clin Microbiol Antimicrob       Date:  2002-09-16       Impact factor: 3.944

2.  The TNF-alpha system: functional aspects in depression, narcolepsy and psychopharmacology.

Authors:  Mark Berthold-Losleben; Hubertus Himmerich
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.